Ebrahim Umer: The Sickest Liver Patients Deserve One Language – Lessons from the Kyoto Consensus
Ebrahim Umer, Gastroenterology and Hepatology Fellow at St. Paul’s Hospital Millennium Medical College, shared a post on LinkedIn:
“The Sickest Liver Patients Deserve One Language – Lessons from the Kyoto Consensus
One of the most important challenges in modern hepatology is that two clinicians may look at the same patient with advanced chronic liver disease and arrive at different diagnoses of Acute-on-Chronic Liver Failure (ACLF) depending on which international criteria they follow.
The concept of ACLF has transformed our understanding of liver decompensation. It is no longer viewed simply as worsening cirrhosis, but rather as a distinct syndrome characterized by acute deterioration, systemic inflammation, organ failure, and high short-term mortality.
Yet, despite its clinical importance, a universal definition remains elusive.
Today, three major societies continue to use different diagnostic frameworks:
- EASL-CLIF focuses heavily on extrahepatic organ failures and grades ACLF according to the number of failed organs.
- APASL emphasizes acute hepatic insult leading to jaundice and coagulopathy, followed by ascites and/or encephalopathy within a defined time frame.
- NACSELD primarily evaluates extrahepatic organ failures in hospitalized patients with cirrhosis.
As a result, the same patient may be classified as ACLF by one society and not by another. This diagnostic heterogeneity affects epidemiology, clinical decision-making, transplant prioritization, research outcomes, and even communication among hepatologists worldwide.
Beyond definitions lies a human reality.
The patient in front of us is not an EASL patient, an APASL patient, or a NACSELD patient. They are a critically ill individual whose prognosis can change dramatically within days. Delayed recognition may mean missed opportunities for intensive management, liver transplantation, or life-saving interventions.
This is why ongoing international efforts toward harmonization are so important.
The emerging Kyoto Consensus represents a significant step toward bridging Eastern and Western perspectives on ACLF. Rather than focusing on differences, it seeks common ground—acknowledging the diverse pathophysiologic pathways of ACLF while moving the field closer to a globally accepted framework for diagnosis, prognostication, and management.
As hepatologists, our ultimate goal is not merely to define ACLF better, but to identify it earlier, treat it more effectively, and improve survival for some of the sickest patients we care for.”
Stay updated with Hemostasis Today.
-
Jun 4, 2026, 13:45Edward Lee Carter: The First-Ever AHA/ACC Acute PE Guideline Is Here
-
Jun 4, 2026, 13:38Denis Oduor: The Role of Expectant Fathers in Saving Mothers and Newborns
-
Jun 4, 2026, 13:36Mohammad Reza Moghaddasnejad: Platelet Activation as a Key Driver of Breast Cancer Progression
-
Jun 4, 2026, 13:31Fredrick Chalinga: Microcytic Anemia Does Not Always Mean Iron Deficiency
-
Jun 4, 2026, 13:23How Access to Care Changed One Life – WFH
-
Jun 4, 2026, 13:16Muhammad Usman Arshad: Meta-Analysis Supports Expanding Role of DOACs in Cancer-Associated Thromboembolism
-
Jun 4, 2026, 12:59Dual Prognostic Significance of P2RY12 in Antithrombotic-Treated STEMI – JTH
-
Jun 4, 2026, 12:43Beth Wallace: Raising Awareness of Hereditary Haemochromatosis
-
Jun 4, 2026, 11:57José María Bastida Bermejo: IPDs Help to Better Understand Platelet Biogenesis and Function